Long-term outcomes of isolated limb perfusion with hyperthermia in patients with soft tissue sarcomas

Т.К. Харатишвили, Н.С. Петроченко, Елена Грибкова, Ю. Буйденок, С. М. Каспшик, Мамед Джавадович Алиев, T. Kharatishvili, N. S. Petrochenko, Elizaveta I. Gribkova, Yuri V. Buidenok, S. Kaspshik, M. D. Aliyev
{"title":"Long-term outcomes of isolated limb perfusion with hyperthermia in patients with soft tissue sarcomas","authors":"Т.К. Харатишвили, Н.С. Петроченко, Елена Грибкова, Ю. Буйденок, С. М. Каспшик, Мамед Джавадович Алиев, T. Kharatishvili, N. S. Petrochenko, Elizaveta I. Gribkova, Yuri V. Buidenok, S. Kaspshik, M. D. Aliyev","doi":"10.47093/2218-7332.2023.14.2.31-38","DOIUrl":null,"url":null,"abstract":"In case of locally advanced soft tissue sarcomas of the extremities (STS), the large size of which does not allow resection with preservation of the limb, isolated regional perfusion (IRP) of the limb is considered as one of the effective treatment options.Aim. To evaluate the long-term outcomes of IRP with melphalan under conditions of hyperthermia for treatment of locally advanced STS of the extremities.Materials and methods. We conducted a prospective cohort clinical study that included 42 patients with STS of the extremities. All patients underwent IRP with melphalan, in one case – in combination with tumor necrosis factor alpha. Additional lymph node dissection was performed in 8 cases (19%). The 5-year overall survival was estimated by the Kaplan-Meier method.Results. The median age of the patients was 50 years (from 24 to 80 years), women predominated – 32 (76%). STS of the upper limb was diagnosed in 14 patients (33%), of the lower limb in 28 (67%). G3 grade was verified in 34 (81%) patients, in the rest – G2. Most patients had a recurrent tumor – in 34 (81%) cases. All patients received previous treatment: surgery in combination with chemotherapy and / or radiation therapy – 36 (86%), chemotherapy alone – 2 (5%), surgery alone – 4 (9%) patients. Within 5 years, tumor recurrence developed in 20 (48%) patients, amputation was performed in 10 (24%) patients, distant metastases were diagnosed in 4 (10%) patients. The mean time to relapse after IPC was 9.3 ± 3.5 months. Overall survival at 1, 2, 3, 4, and 5 years was 98%, 88%, 86%, 74%, and 67%, respectively.Conclusion. IRP under conditions of hyperthermia with melphalan is an effective method for the treatment of STS of the extremities: the overall 5-year survival rate is 67% with a low rate of amputations and metastasis.","PeriodicalId":129151,"journal":{"name":"Sechenov Medical Journal","volume":"82 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sechenov Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47093/2218-7332.2023.14.2.31-38","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In case of locally advanced soft tissue sarcomas of the extremities (STS), the large size of which does not allow resection with preservation of the limb, isolated regional perfusion (IRP) of the limb is considered as one of the effective treatment options.Aim. To evaluate the long-term outcomes of IRP with melphalan under conditions of hyperthermia for treatment of locally advanced STS of the extremities.Materials and methods. We conducted a prospective cohort clinical study that included 42 patients with STS of the extremities. All patients underwent IRP with melphalan, in one case – in combination with tumor necrosis factor alpha. Additional lymph node dissection was performed in 8 cases (19%). The 5-year overall survival was estimated by the Kaplan-Meier method.Results. The median age of the patients was 50 years (from 24 to 80 years), women predominated – 32 (76%). STS of the upper limb was diagnosed in 14 patients (33%), of the lower limb in 28 (67%). G3 grade was verified in 34 (81%) patients, in the rest – G2. Most patients had a recurrent tumor – in 34 (81%) cases. All patients received previous treatment: surgery in combination with chemotherapy and / or radiation therapy – 36 (86%), chemotherapy alone – 2 (5%), surgery alone – 4 (9%) patients. Within 5 years, tumor recurrence developed in 20 (48%) patients, amputation was performed in 10 (24%) patients, distant metastases were diagnosed in 4 (10%) patients. The mean time to relapse after IPC was 9.3 ± 3.5 months. Overall survival at 1, 2, 3, 4, and 5 years was 98%, 88%, 86%, 74%, and 67%, respectively.Conclusion. IRP under conditions of hyperthermia with melphalan is an effective method for the treatment of STS of the extremities: the overall 5-year survival rate is 67% with a low rate of amputations and metastasis.
软组织肉瘤患者孤立肢体灌注热疗的长期预后
对于局部进展期肢体软组织肉瘤(STS),由于其体积较大,无法切除且保留肢体,肢体局部局部灌注(IRP)被认为是有效的治疗方法之一。目的:评价热疗条件下melphalan联合IRP治疗肢体局部晚期STS的长期疗效。材料和方法。我们进行了一项前瞻性队列临床研究,纳入了42例四肢STS患者。所有患者都接受了美法兰的IRP治疗,其中一例是联合肿瘤坏死因子。另外行淋巴结清扫8例(19%)。用Kaplan-Meier法估计5年总生存率。患者年龄中位数为50岁(24 ~ 80岁),女性占多数,32岁(76%)。上肢STS 14例(33%),下肢STS 28例(67%)。34例(81%)患者为G3级,其余为G2级。大多数患者有复发肿瘤,34例(81%)。所有患者均接受过既往治疗:手术联合化疗和/或放疗36例(86%),单独化疗2例(5%),单独手术4例(9%)。5年内,20例(48%)患者出现肿瘤复发,10例(24%)患者截肢,4例(10%)患者被诊断为远处转移。IPC术后平均复发时间为9.3±3.5个月。1年、2年、3年、4年和5年的总生存率分别为98%、88%、86%、74%和67%。melphalan热疗条件下的IRP是治疗四肢STS的有效方法:总5年生存率为67%,截肢和转移率低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信